Axonics, Inc. (AXNX)
Axonics, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $70.98, giving a market capitalisation of $3.63B. On trailing twelve-month figures it carries a trailing P/E of -591.50, a net margin of -1.7%. Its beta of 0.83 implies it has historically moved less than the broad market.
Axonics, Inc. is a medical device firm that focuses on developing and bringing to market sacral neuromodulation (SNM) solutions. These advanced SNM systems are designed to address a range of medical conditions, such as overactive bladder (including urinary urge incontinence and frequent urges to urinate), alongside fecal incontinence and non-obstructive urinary retention. The company's flagship rechargeable SNM System, known as r-SNM, operates by delivering gentle electrical impulses to specific sacral nerves, aiming to restore regular communication between the brain and the bladder or bowel, thereby lessening the symptoms of their dysfunction. Beyond its SNM portfolio, Axonics also provides Bulkamid, a urethral bulking agent for managing stress urinary incontinence in women. The firm distributes its offerings both through its dedicated sales team and a network of distributors across the United States, the United Kingdom, Germany, the Netherlands, the Nordic region, and other international markets. Established in 2012 and headquartered in Irvine, California, the company was initially known as Axonics Modulation Technologies, Inc., before officially changing its name to Axonics, Inc. in March 2021.
Axonics, Inc. is most often compared with the following Healthcare names: